Development of tools to facilitate palliative and supportive care referral for patients with idiopathic pulmonary fibrosis

2017 ◽  
Vol 8 (3) ◽  
pp. 340-346 ◽  
Author(s):  
Charles Sharp ◽  
Heather Lamb ◽  
Nikki Jordan ◽  
Adrienne Edwards ◽  
Rachel Gunary ◽  
...  

ObjectivesPalliative care is underused in non-malignant respiratory diseases, including interstitial lung diseases (ILDs). We investigated current practices around palliative and supportive care and explored the impact of a supportive care decision aid tool.MethodsThis was a single centre study in a UK ILD centre. Retrospective analysis of hospice referrals and patients with idiopathic pulmonary fibrosis (IPF) under the Bristol ILD (BILD) service were used to identify unmet palliative and supportive care needs. Using quality improvement methodology, we explored the impact of a supportive care decision aid on clinician behaviours for patients with ILD.Results108 patients with ILD were referred for hospice care between 2010 and 2015, representing 0.15% of all referrals, compared with a population prevalence of IPF of 0.9%. The median interval between referral and death was 124 days.Records were reviewed for 64 deceased and 89 living patients with IPF seen on July–December 2014. The decision aid was prospectively assessed with 73 patients. The deceased patients had greater markers of severity. There were no other differences between the groups.After introduction, the decision aid tool was completed for 49.3% of patients and resulted in significant increases in documented discussion of referral to palliative care (11.2%vs53.6%, p<0.01) and end-of-life discussions (15.7%vs91.8%, p<0.01). Tool completion led to an increase in referral for palliative care (2.7%vs16.7%, p<0.01).ConclusionPalliative care services are underused in ILD and a supportive care decision aid can prompt consideration of palliative and supportive care needs.

Author(s):  
Charles Sharp ◽  
Adrienne Edwards ◽  
Heather Lamb ◽  
Sorayya Alam ◽  
Nikki Jordan ◽  
...  

2014 ◽  
Vol 23 (3) ◽  
pp. 779-789 ◽  
Author(s):  
Zoe Stamataki ◽  
L. Brunton ◽  
P. Lorigan ◽  
A. C. Green ◽  
J. Newton-Bishop ◽  
...  

Heart & Lung ◽  
2017 ◽  
Vol 46 (1) ◽  
pp. 24-29 ◽  
Author(s):  
Kathleen Oare Lindell ◽  
Dio Kavalieratos ◽  
Kevin F. Gibson ◽  
Laura Tycon ◽  
Margaret Rosenzweig

2020 ◽  
Author(s):  
Udhayvir Singh Grewal ◽  
Stephanie Terauchi ◽  
Muhammad Shaalan Beg

UNSTRUCTURED It has been reported that the incidence of SARS-CoV-2 infection is higher in patients with cancer than in the general population and that patients with cancer are at an increased risk of developing severe life-threatening complications from COVID-19. Increased transmission and poor outcomes noted in emerging data on patients with cancer and COVID-19 call for aggressive isolation and minimization of nosocomial exposure. Palliative care and oncology providers are posed with unique challenges due to the ongoing COVID-19 pandemic. Telepalliative care is the use of telehealth services for remotely delivering palliative care to patients through videoconferencing, telephonic communication, or remote symptom monitoring. It offers great promise in addressing the palliative and supportive care needs of patients with advanced cancer during the ongoing pandemic. We discuss the case of a 75-year-old woman who was initiated on second-line chemotherapy, to highlight how innovations in technology and telehealth-based interventions can be used to address patients’ palliative and supportive care needs in the ongoing epidemic.


2018 ◽  
Vol 5 (1) ◽  
pp. e000272 ◽  
Author(s):  
Kathleen Oare Lindell ◽  
Mehdi Nouraie ◽  
Melinda J Klesen ◽  
Sara Klein ◽  
Kevin F Gibson ◽  
...  

IntroductionIdiopathic pulmonary fibrosis (IPF), a progressive life-limiting lung disease affects approximately 128 000 newly diagnosed individuals in the USA annually. IPF, a disease of ageing associated with intense medical and financial burden, is expected to grow in incidence globally. Median survival from diagnosis is 3.8 years, and many of these patients succumb to a rapid death within 6 months. Despite the fatal prognosis, we have found that patients and caregivers often fail to understand the poor prognosis as the disease relentlessly progresses. Based on feedback from patients and families living with IPF, we developed the S-Symptom Management, U-Understanding the Disease, P-Pulmonary Rehabilitation, P-Palliative Care, O-Oxygen Therapy, R-Research Considerations and T-Transplantation (‘SUPPORT') intervention to increase knowledge of the disease, teach self-management strategies and facilitate preparedness with end of life (EOL) planning.MethodsThis study is a randomised trial to test the efficacy of SUPPORT intervention compared with routine care in patients with IPF and their caregivers delivered after three clinical visits. We are recruiting a cohort of 64 new IPF patient/caregiver dyads (32 for each dyad).ResultsThe trial will evaluate whether the SUPPORT intervention decreases stress, improves symptom burden, quality of life, preparedness and advance care planning for patients and caregivers, quality of dying and death for caregivers if the patient dies during the course of the study, as well as assess the impact of primary palliative care on healthcare resource use near the EOL.ConclusionBy increasing knowledge of the disease, teaching self-management strategies and facilitating preparedness with EOL planning, we will address a critical gap in the care of patients with IPF.Trial registration numberNCT02929017; Pre-results.


Sign in / Sign up

Export Citation Format

Share Document